Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials

Jin-Tai Yu,1 Wei Xu,2 Chen-Chen Tan,2 Sandrine Andrieu,3 John Suckling,4 Evangelos Evangelou,5 An Pan,6 Can Zhang,7 Jianping Jia,8 Lei Feng,9 Ee-Heok Kua,9 Yan-Jiang Wang,10 Hui-Fu Wang,2 Meng-Shan Tan,2 Jie-Qiong Li,2 Xiao-He Hou,2 Yu Wan,2 Lin Tan,2 Vincent Mok,11 Lan Tan,2 Qiang Dong,1 Jacques Touchon,12 Serge Gauthier,13 Paul S Aisen,14 Bruno Vellas15

ABSTRACT
Background Evidence on preventing Alzheimer's disease (AD) is challenging to interpret due to varying study designs with heterogeneous endpoints and credibility. We completed a systematic review and meta-analysis of current evidence with prospective designs to propose evidence-based suggestions on AD prevention.

Methods Electronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OPSs) and randomised controlled trials (RCTs) were included. The multivariable-adjusted effect estimates were pooled by random-effects models, with credibility assessment according to its risk of bias, inconsistency and imprecision. Levels of evidence and classes of suggestions were summarised.

Results A total of 44 676 reports were identified, and 243 OPSs and 153 RCTs were eligible for analysis after exclusion based on pre-decided criteria, from which 104 modifiable factors and 11 interventions were included in the meta-analyses. Twenty-one suggestions are proposed based on the consolidated evidence, with Class I suggestions targeting 19 factors: 10 with Level A strong evidence (education, cognitive activity, high body mass index in late-life, hyperhomocysteinaemia, depression, stress, diabetes, head trauma, hypertension in midlife and orthostatic hypotension) and 9 with Level B weaker evidence (obesity in midlife and late-life, physical exercise, smoking, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C). In contrast, two interventions are not recommended: oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B).

Interpretation Evidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.

INTRODUCTION
An unequivocal downturn in the prevalence and incidence of dementia was recently reported and associated with earlier population-level investment (eg, improved education and vascular health),1–4 strengthening the necessity for primary prevention.4

The past few decades have witnessed great global efforts in updating and upgrading the evidence on how to prevent Alzheimer’s disease (AD),5,6 accounting for approximately two-thirds of all cases of dementia and affecting up to 20% of individuals older than 80 years.7,8 Nevertheless, key issues in the field are the inconsistency among conclusions and variable levels of credibility arising from the wide variety of study designs.9 Two types of studies are generally regarded as having the greatest impact on the extant literature: (1) observational prospective studies (OPSs), which describe temporal relationships with potential causal links and often use large samples recruited from community dwellers; and (2) randomised controlled trials (RCTs), which possess strong internal validity to infer causality by testing the effects of specific interventions on the incidence of AD. Although both approaches are useful, the major concerns in OPSs are usually the elusive sources of bias when interpreting the identified wide-ranging factors, and current RCTs are often compromised by short follow-up durations, subjective endpoints, small sample sizes and specific recruitment criteria with uncertain generalisability.5

Considerable evidence has been generated regarding AD through OPSs and RCTs. Because it is almost impossible to conduct RCTs that evaluate all risk factors of AD, a quantitative depiction of AD’s prevention ‘profile’ based on these two complementary study types is urgently needed for prevention guidelines that weigh the benefits against the risks. Deconstructing the bias sources from OPSs will facilitate the interpretation of credibility ratings and also guide future research directions. In this study we consolidated the extant evidence from both OPSs and RCTs to formulate the levels of evidence and classes of clinical suggestions for AD prevention.

METHODS
Search strategy and selection criteria
We followed the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2009 guidelines,10,11 PubMed,
Cognitive neurology

Figure 1 Flow chart showing literature selection for OPSs (figure 1A) and RCTs (figure 1B) and map depicting studies eligible for systematic review (figure 1C). A total of 243 OPSs (figure 1A) and 153 completed RCTs (figure 1B) were finally included. 243 OPSs from 17 countries on four continents (Europe accounting for 43%, North America 41%, Asia 14% and Latin America 2%) reported the association of 134 modifiable risk factors with risk of clinical Alzheimer’s-type dementia (83% used all AD, 13% probable AD and 11% pure AD) diagnosed by NINCDS-ADRDA criteria in populations with various racial backgrounds (68% white, 14% Asian descent, 13% mixed race), sources (84% community, 6% institution, 10% mixed source) and baseline cognitive statuses (82% free of dementia, 16% cognitively normal, 2% unclear). A total of 153 published RCTs from five continents (North America accounting for 45%, Europe 36%, Australia 9%, Asia 7% and Latin America 3%) reported the effects of 15 types of interventions on AD (7%), dementia (16%) and cognitive function (85%) in selected participants, including elderly subjects (37%), high-risk group (35%) or cognitively impaired (28%) (figure 1C). In the pie charts, 1 and 2 show the outcome (all AD=probable or possible AD, or AD with or without VD/CVD, Pure AD=AD without VD or CVD; A=Alzheimer’s disease, B=Biomarker of AD, C=Cognition, D=Dementia); 3 and 4 show the population source; 5 and 6 show the percentage of studies from different continents. AD, Alzheimer’s disease; CVD, cerebrovascular disease; OPS, observational prospective study; RCT, randomised controlled trial; VD, vascular dementia.

EMBASE and CENTRAL were searched using the terms “Alzheimer’s”, “Alzheimer”, “dementia”, and “risk” for OPS and “Alzheimer”, “cognitive”, “cognition”, “prevent”, and “prevention” for RCT up to 1 March 2019. Bibliographies of relevant literature and records in Clinicaltrials.gov and AlzRisk database12 were hand-searched in case of omission. The inclusion criteria were as follows: (1) an OPS exploring the association between potentially modifiable exposures at baseline and incident AD independently diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria,13 or (2) a RCT targeting the impact of addressing modifiable risk factors on the incidence of AD or AD-related clinical endpoints (dementia or cognitive impairment), and (3) a publication written in English to permit easy access to the source information of all included articles. The detailed exclusion criteria are shown in figure 1. Bibliographies of relevant original studies and systematic reviews were hand-searched. Literature selection was performed by three pairs of experienced investigators (JTY, WX, CCT, HFW, MST and JQL) and any disagreements on inclusion were resolved by consensus and arbitration by a panel of investigators within the review team (JTY, WX, CCT, HFW, MST, JQL and Lan Tan).

Data extraction

Pre-designed templates were used to extract the data with reference to the STROBE statement (https://www.equator-network.org/reporting-guidelines/strobe/). An evidence-based profile of AD modifiable risk factors was established for better tracing of bias sources. The multivariable-adjusted risk estimates were extracted. If these estimates were unavailable, we attempted to obtain them by contacting the corresponding authors. The stringently performed process comprised three independent steps: (a) data extraction by three pairs of experienced investigators (JTY, WX, CCT, HFW, MST and JQL); (b) independent data proof reading by 10 researchers (JTY, WX, CCT, HFW, MST, JQL, XHH, YY, Lin Tan and Lan Tan); and (c) addressing discrepancies by consensus and arbitration.
Assessment of study quality and credibility of meta-analyses

The risk of bias tool proposed by Cochrane for RCTs and involving the Newcastle–Ottawa Quality Assessment Scale (NOS) for OPSs was used to evaluate the quality of eligible studies. The credibility of each result was then categorised into four levels: Good (G level), Acceptable (A± level), Susceptible (S± level) and Poor (P level) according to the score combination of three domains: risk of bias, inconsistency and imprecision. Levels of evidence were summarised, representing the quality of scientific evidence on the basis of directness of outcome (for RCTs), consistency and quality of data from clinical trials and/or observational studies. Classes of suggestions were made after weighing the benefits against the risks due to specific interventions. *Factors rated with ‘level C’ evidence were not considered for recommendation in the present study.

Levels of evidence and strength of suggestions

Levels of evidence were summarised to represent the quality of scientific evidence on the basis of directness of outcome for AD, credibility of meta-analyses and consistency of evidence from clinical trials and/or observational studies: Level A>Level B>Level C (based on the evidence level). Classes of recommendations were made after weighing the benefits against the risks due to specific interventions: Class I (strong recommendation), Class II (weak recommendation) and Class III (not recommended) (figure 2).

Statistical analyses

The multivariable-adjusted risk estimates and 95% confidence intervals (CI) were log-transformed and combined using random models (DerSimonian–Laird method). Sensitivity analyses excluding odd ratios (ORs) reported by some OPSs were performed because ORs tend to overestimate the effect size compared with the relative risk (RR), particularly when the incidence is not small. A 95% prediction interval (PI) was calculated to better evaluate the precision of the result. Heterogeneity was assessed by Q test and quantified by the I² metric. The source of heterogeneity was explored via sensitivity analyses, meta-regression and subgroup analyses. The robustness of the results was examined by excluding those rated as at a higher risk of bias. Publication bias was assessed following two steps: (1) testing the symmetry of the funnel plot by the Egger method; and (2) determining whether any asymmetry was due to publication bias via enhanced-contour funnel plots after the trim-and-fill method. The meta-regression and publication bias test were conducted only when at least 10 studies were available. The “metagen”, “metabias” and “trimfill” packages in R 3.4.3 software (https://www.r-project.org) were used to perform all the analyses.

Additionally, multiple subgroup and sensitivity analyses were conducted to take into account the following cases where results might be biased. First, 82% of studies recruited people without dementia at baseline and only 17% specifically constrained the population to those with normal cognition. Notably, inclusion of individuals with mild cognitive impairment, who might be at a prodromal stage of AD, resulted in a degree of misclassification bias, especially when the population was at an advanced age and was insufficiently followed. Thus, subgroup analyses according to the cognitive status at baseline (free of dementia vs cognitively normal), sufficiency of follow-up (online supplementary appendix 1) and life stage were performed. Second, it was often clinically difficult to distinguish mixed AD (coexistence of AD and vascular dementia (VD)) from VD among elderly people, especially when the pathological evidence is often unavailable and the individual has a history of stroke. Thus, to examine the influence of potential misclassification bias, subgroup analyses based on AD outcomes (all AD vs probable or pure AD (p-AD) defined as AD without VD or cerebrovascular disease (CVD)) were performed. Third, sensitivity analyses excluding studies with high attrition rates and poor generalisability (online supplementary appendix 1) were conducted.

Patient involvement

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There
are no plans to disseminate the results of the research to study participants or the relevant patient community. No evaluation was undertaken to determine whether the studies included in the review had any patient involvement.

RESULTS

Figure 1 shows the flow diagrams of the study selection process for OPSs (figure 1A) and RCTs (figure 1B). The search yielded 33,145 and 11,531 records for OPSs and RCTs, respectively. After integration with the AlzRisk database and Clinicaltrials.gov website, a total of 243 OPSs and 153 completed RCTs were finally included. Evidence-based profiles were constructed (online supplementary appendix 3 & 4). The global distribution of studies eligible for the systematic review and their characteristics are shown in figure 1C. The sources of bias for the current evidence profile mainly consisted of generalisability, attrition and misclassification for OPSs and performance bias, incomplete outcome data, inadequate allocation concealment and selective outcome reporting for RCTs (online supplementary appendix figure 1).

Meta-analyses were conducted for 134 risk factors (online supplementary appendix 5). A total of 43 factors showed significant associations with the risk of AD, among which 80% were identified as significantly modifying the risk by at least 25% (figure 3A). Indicating the credibility of pooled results, analyses for eight risk factors (diabetes, orthostatic hypotension, hypertension in midlife, head trauma, stress, depression, midlife obesity and coronary artery bypass grafting (CABG) surgery) and three protective factors (cognitive activity, increased BMI in late life and education) were rated with moderate-to-high credibility (G, G/A+ or A+ level). In addition, 20 factors were rated at a low-to-moderate level (A+/A− or A− level) and 12 were rated at a very low level (S+, S− or P level) (figure 3B).

For the directness of the outcomes, only five meta-analyses (involving acetylcholinesterase inhibitor treatment, non-steroidal anti-inflammatory drugs (NSAIDs), hormone replacement therapy and ginkgo biloba) examined associations with AD (figure 4A). For the levels of credibility, nine meta-analyses were conducted on a moderate-to-high level (G, G/A+ or A+ level). The remaining 29 meta-analyses were conducted on other levels.
Figure 4  Risk of bias profile, meta-analysis results, sample size (figure 4A), credibility rating (figure 4B) and summary (figure 4C) for 11 interventions based on randomised controlled trials. When the mean score (for each bias domain) ≤0.5 was regarded as possibly moderate-to-high risk, 17.2% meta-analyses had problems of inadequate concealment of allocations, 27.6% for performance bias, 3.4% for detection bias, 24.1% for incomplete outcome data, 13.8% for selective outcome reporting and 31% for other sources of bias. For the significance of the pooled results, six meta-analyses showed significant associations (figure 4A). For credibility of the pooled results, nine meta-analyses were rated at a moderate-to-high level (G; G/A+ or A+ level), three at a low-to-moderate level (A+/A− or A− level) and 17 at a very low level (S+, S− or P level). Specifically, moderate-to-high credibility of results showed little benefit on the risk of Alzheimer’s disease from acetycholinesterase inhibitors, antihypertensive agents in late life, oestrogen therapy, and DHA+PA supplementation. No robust conclusion could be reached for non-steroidal anti-inflammatory drugs, ginkgo biloba, cocoa flavanol and cognitive training. For directness of outcomes, five meta-analyses examined the associations with AD (figure 4B). Although none showed a good performance in all the above domains, two interventions (physical exercise and total homocysteine-lowering treatment) seem more promising than others (figure 4C).

21 evidence-based suggestions with different levels and strength of evidence (11 with Level A and 10 with Level B) are listed in table 1. Specifically, Class I suggestions were for 19 factors, including 10 factors with Level A evidence (cognitive activity, hyperhomocysteinaemia, increased BMI in late life, depression, stress, diabetes, head trauma, hypertension in midlife, orthostatic hypotension and education) and nine factors with Level B evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, CVD, frailty, atrial fibrillation and vitamin C) (figure 5). Two factors were not recommended (Class III): oestrogen replacement therapy (Level A) and acetylcholinesterase inhibitors (Level B) (online supplementary appendix 7 & appendix figure 6). Six factors (diastolic blood pressure management, NSAID use, social activity, osteoporosis, pesticide exposure and silicon from drinking water) were rated as Level C low-strength evidence, with the recommendation that their relationships with AD be confirmed in future studies.

DISCUSSION

Our systematic review and meta-analysis identified a total of 21 evidence-based suggestions that can be used in life-course management of AD.
practices to prevent AD. Nineteen were regarded as ‘strong suggestions’, nine of which were rated with Level A evidence (table 1). Nearly two-thirds of these suggestions target vascular risk factors and lifestyle, strengthening the importance of keeping a good vascular condition and maintaining a healthy lifestyle for preventing AD.

Strengths and weaknesses of this study
This is the most comprehensive and large-scale systematic review and meta-analysis for AD prevention to date. The evidence-based suggestions are constructed by integrating a large amount of evidence from both OPSs and RCTs. Sources of bias and robustness of evidence were thoroughly assessed and secondary analyses were used to explore their influences, guaranteeing the objectivity and transparency of our findings. Furthermore, the outcome of OPSs was confined to AD dementia, given that the heterogeneity of endpoints might complicate the profile and downgrade the credibility of the evidence because: (1) observational studies are more vulnerable to sources of bias than RCTs, even though a rigorous procedure was employed to grade the evidence; (2) non-AD dementia accounts for roughly 30% of incident dementia (online supplementary appendix figure 7) and the false positive rate for diagnosis of mild cognitive impairment is fairly common. Some caveats should also be emphasised. Observational studies cannot indicate causal relationships and RCTs may not be generalisable beyond the specific sample, intervention, dose and duration studied. Classification of the available evidence including assessment of potential biases requires subjective judgement. The values of the current suggestions might be confined by geographic variability, definition of exposure and prevalence of risk factors at the population level. Some important factors of all-cause dementia were inadequately investigated for AD, such as social determinants and frailty, and more high-quality prospective studies are warranted to bridge this gap. AD is challenging to study. The neuropathology of AD begins at least 15 years before symptoms appear. Tools such as amyloid and tau PET scanning are available to characterise the neuropathology at any stage, but it is impractical to include such assessments in large observational studies; without biomarker data, misclassification is unavoidable and several conclusions may be challenged by studies in the near future. Despite these challenges, this systematic review and meta-analysis can suggest recommendations to guide clinicians, even as the field perseveres with additional studies. These evidence-based suggestions must be presented in the context of the limitations of the studies and continuing uncertainty among investigators. Finally, the present study did not register and the protocol can be found in online supplementary appendix 8.

Strengths and weaknesses in relation to other studies
Notably, tHcy-lowering treatment seems the most promising intervention for AD prevention, in agreement with a recent

<table>
<thead>
<tr>
<th>Factors/interventions</th>
<th>Suggestion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lifestyle</strong></td>
<td></td>
</tr>
<tr>
<td>BMI and weight management</td>
<td>Adults aged ≤ 65 years should maintain or lose weight through an appropriate balance of physical activity, caloric intake and formal behavioural programmes when indicated to maintain/achieve a BMI between 18.5 and 24.9 kg/m² (Class I, Level B)</td>
</tr>
<tr>
<td></td>
<td>Adults aged ≥ 65 years should not to be too skinny (Class I, level A4)</td>
</tr>
<tr>
<td></td>
<td>Adults aged ≥ 65 years with a trend of weight loss should be closely monitored for their cognitive status (Class I, Level B)</td>
</tr>
<tr>
<td><strong>Physical exercise</strong></td>
<td>Individuals, especially those aged ≥ 65 years, should stick to regular physical exercise (Class I, Level B)</td>
</tr>
<tr>
<td><strong>Cognitive activity</strong></td>
<td>Mentally stimulating activities should be encouraged, such as reading, playing chess, etc (Class I, Level A4)</td>
</tr>
<tr>
<td><strong>Smoking</strong></td>
<td>People should not smoke and should avoid environmental tobacco smoke. Counselling, nicotine replacement and other pharmacotherapy as indicated should be provided in conjunction with a behavioural programme or formal smoking cessation programme (Class I, Level B)</td>
</tr>
<tr>
<td><strong>Sleep</strong></td>
<td>Get sufficient and good quality sleep and consult a doctor or receive treatment when you have problem with sleep (Class I, Level B)</td>
</tr>
<tr>
<td><strong>Comorbidities</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes</strong></td>
<td>Stay away from diabetes via a healthier lifestyle and diabetic patients should be closely monitored for their cognitive decline (Class I, Level A4)</td>
</tr>
<tr>
<td><strong>CVD</strong></td>
<td>Maintain a good condition of the cerebral vessels via a healthier lifestyle or medications to avoid arteriosclerosis, low cerebral perfusion and any CVD. Individuals with stroke, especially cerebral microbleeding, should be carefully monitored for their cognitive change and take preventative measures as indicated to protect cognition (Class I, Level B)</td>
</tr>
<tr>
<td><strong>Head trauma</strong></td>
<td>Protect your head from injuries (Class I, level A4)</td>
</tr>
<tr>
<td><strong>Frailty</strong></td>
<td>Stay healthy and strong in late life. Those with increasing frailty should be especially monitored for their cognition (Class I, Level A4)</td>
</tr>
<tr>
<td><strong>Blood pressure</strong></td>
<td>Individuals aged &lt; 65 years should avoid hypertension via a healthier lifestyle (Class I, Level A4)</td>
</tr>
<tr>
<td></td>
<td>Individuals with DH should be closely monitored for their cognition (Class I, Level A4)</td>
</tr>
<tr>
<td><strong>Depression</strong></td>
<td>Maintain a good condition of mental health and closely keep an eye on the cognitive status for those with depressive symptoms (Class I, Level A4)</td>
</tr>
<tr>
<td><strong>AF</strong></td>
<td>Maintain a good cardiovascular condition and manage AF using pharmaceuticals (Class I, Level B)</td>
</tr>
<tr>
<td><strong>Stress</strong></td>
<td>Relax your mind and avoid daily stress (Class I, Level A4)</td>
</tr>
<tr>
<td><strong>Other domains</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Education</strong></td>
<td>Receive as much education as possible in early life (Class I, level A4)</td>
</tr>
<tr>
<td><strong>Hyperhomocysteinaemia</strong></td>
<td>Have a regular blood examination for homocysteine level. Individuals with hyperhomocysteinaemia should be treated with vitamin B and/or folic acid and be followed with a focus on their cognition (Class I, Level A2)</td>
</tr>
<tr>
<td><strong>Vitamin C</strong></td>
<td>Vitamin C in the diet or taken as supplements might help (Class I, Level B)</td>
</tr>
<tr>
<td><strong>ERT</strong></td>
<td>Oestrogen replacement therapy should not be specifically used for AD prevention in postmenopausal women (Class III, Level A2)</td>
</tr>
<tr>
<td><strong>ACI</strong></td>
<td>ACI should not be used for AD prevention in cognitively impaired individuals (Class III, Level B)</td>
</tr>
</tbody>
</table>

*The risk of bias is rated as high mainly due to lack of a blinding method and allocation concealment, which however cannot be achieved in randomised controlled trials for interventions such as physical exercise. We therefore consider that the results are relatively more reliable than rated. Also, the content cannot be too detailed (especially for the dose and duration) for some factors and a very good trial is needed to replicate (pivotal studies). Also, these suggestions must be presented in the context of the limitations of the studies and continuing uncertainty among investigators.

ACI, acetylcholinesterase inhibitors; AF, atrial fibrillation; BMI, body mass index; CVD, cerebrovascular disease; ERT, estrogen replacement therapy; IMT, intima-media thickness; NSAIDs, non-steroidal anti-inflammatory drugs; DH, orthostatic hypotension.
The Lancet Commission on dementia has recently proposed nine potentially modifiable risk factors of all-cause dementia. However, these suggestions might not be directly applicable to AD, bearing in mind that the heterogeneity of endpoints complicates the profile and reduces the credibility of evidence for AD prevention. Our study generated more evidence-based suggestions associated with a decreased risk of AD, filling this gap in the field.

Meaning of the study
The hypotheses for the underlying mechanisms may include brain reserve theory, the hypoperfusion hypothesis, one-carbon metabolism, hypomethylation theory, inflammation and the oxidative stress hypothesis. The combination of multiple recommendations is most likely the best approach to delay the onset of AD, as indicated by the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). On the basis of this paper, future clinical trials should focus on exploring the best combination of recommendations with Class I recommendation and Level A evidence to prevent AD using larger samples, particularly in real-world settings. These evidence-based suggestions should be particularly noted by non-demented but high-risk individuals (eg, people with APOEε4, a high polygenic score, a family history of dementia or amyloid-positive evidence) and family doctors to give optimal recommendations to their patients in terms of what they might do to get the best protection against AD.

Future research
For OPSs, low participation rates (cognitive activity and stroke), high attrition (stroke, smoking, alcohol drinking and hypertension) and follow-up insufficiency (stroke and smoking) should be specifically highlighted in future prospective studies. Reverse causality might bias the association with late life obesity. It is unclear whether reverse causality exists for other potential factors such as frailty, social isolation and sleep disorders. Investigation and comparison of important characteristics of those who refused to participate or who were lost during follow-up might be a good method to guarantee optimised validity. Subgroup effects exist due to the characteristics of the sample (eg, age, gender, APOEε4 status and medication compliance) or exposure (eg, type, dose and duration). For RCTs, choosing the suitable population might be the key to determining whether an intervention can work. The optimal time window also matters, especially considering that benefits were weak for those with a clinical diagnosis of dementia. Generalisability should be further optimised, such as recruiting larger samples from community-dwelling individuals and searching for methods to lower dropout rates. Well-designed clinical trials are needed to verify the effects on AD of several promising interventions, including sleep improvement, smoking cessation, antidepressant management and antidiabetic agents.

CONCLUSIONS
Twenty-one clinical evidence-based suggestions are proposed, offering clinicians and stakeholders an evidence-based guideline
for AD prevention. With credible though inconclusive evidence, the suggestions targeted 10 risk factors including diabetes, hyperhomocysteinaemia, poor BMI management, reduced education, hypertension in midlife, orthostatic hypotension, head trauma, less cognitive activity, stress and depression. This study provides an advanced and contemporary survey of the evidence, suggesting that more high-quality OPSs and RCTs are urgently needed to strengthen the evidence base for uncovering more promising approaches to preventing AD.

Author affiliations
1 Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
2 Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
3 Department of Epidemiology and Public Health, University of Toulouse III, Toulouse, France
4 Department of Psychiatry, Medical Research Council and Welcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
5 Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece
6 Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
8 Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China
9 Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
10 Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, China
11 Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
12 Department of Neurology, University Hospital of Montpellier, Montpellier, France
13 McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada
14 Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, California, USA
15 Department of Geriatrics, Purpan University Hospital, Toulouse, France

Twitter Wei Xu @na and Can Zhang @martindragconc

Acknowledgements The authors thank Professor Michael M Weiner and Dr Yu-Tzu Wu for critical review.

Contributors JTY and BW conceived and designed the study. JTY, WX, CCT, HPW, MST and JQL selected the articles and extracted the data. JTY, WX, C-CT, HPW, M-ST, J-QL, XHH, WT, LT and LT proofread the data. JTY, WX, C-CT and AP analysed the data. WX and CCT generated the figures. JTY, WX, CCT wrote the first draft of the manuscript. JTY, WX, C-CT, SA, JS, EE, CZ, JJ, AP, LH, EHK, YW, VM, JT, GS, PSA, QD, and BW interpreted the data and contributed to the writing of the final version of the manuscript. All authors agreed with the results and conclusions and approved the final draft.

Funding This study was supported by grants from the National Key R&D Program of China (2018YFC1314702), Shanghai Municipal Science and Technology Major Project (No. 2018SHZDZX03) and ZHANGJIANG LAB.

Competing interests JTY serves as an associate editor-in-chief for Annals of Translational Medicine and is an editor for Journal of Alzheimer’s Disease. SA has received grants from Europe, Ipsen, and France Alzheimer, served as a consultant for Ipsen, Pierre Fabre, Lilly, Nestlé, Sanofi and Servier, and received financial support from Biogen. Nutrition Santé, Pfizer and Icon, and other support from the AMPA Association. GS has received clinical trial support from Lilly and Roche in DIAN-TU, TauRx Therapeutics (TauRx) and Lundbeck; has been a data safety monitoring board (DSMB) member of ADBCS, ATRI, ARI and Eisa; and has been a scientific advisor to Affiris, Boehringer Ingelheim, Lilly, Roche, Servier, Sanofi, Schwabe, Takeda and TauRx. PSA has received grants from the US Alzheimer’s Association, Janssen, Lilly, the US National Institute on Aging and Toyma; and consulting fees from Abbott, Abbvie, Amgen, Anaavex, AstraZeneca, Biogen Idec, Biote, Bristol-Myers Squibb, Cardeus, Cobhar, Eisai, Elan, Eli Lilly, Genentech, Ichor, Iberian, Janssen, Lundbeck, Medivation, Merck, NeuroPhage, Novartis, Pfizer, Piramal, Roche, Somnet and Toyma, outside the submitted work. BW reports grants from Pierre Fabre, Avid, Exonhit, Abbvie, Lilly, Lundbeck, MSD, Otsuka, Regeneron, Sanofi, Roche, AstraZeneca, LPG Systems, Nestlé and Alzheon, and personal fees from Lilly, Lundbeck, MSD, Otsuka, Sanofi, Roche, Sanofi, Biogen, Nestlé, Transition Therapeutics and Takeda.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commerially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Jin-Tai Yu http://orcid.org/0000-0002-7668-0547
Wei Xu http://orcid.org/0000-0002-3310-5875

REFERENCES
20 Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549.
Cognitive neurology


